| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy
|
Siva, S.
|
|
|
26 |
10 |
p. 2196
|
article
|
| 2 |
Academically led clinical trials: challenges and opportunities
|
Turajlic, S.
|
|
|
26 |
10 |
p. 2010-2011
|
article
|
| 3 |
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
|
Van Cutsem, E.
|
|
|
26 |
10 |
p. 2085-2091
|
article
|
| 4 |
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
|
Dijkgraaf, E.M.
|
|
|
26 |
10 |
p. 2141-2149
|
article
|
| 5 |
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
|
Yoshioka, H.
|
|
|
26 |
10 |
p. 2066-2072
|
article
|
| 6 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors
|
Nieto, Y.
|
|
|
26 |
10 |
p. 2125-2132
|
article
|
| 7 |
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
|
Cremolini, C.
|
|
|
26 |
10 |
p. 2092-2097
|
article
|
| 8 |
BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance
|
Eccles, D.M.
|
|
|
26 |
10 |
p. 2057-2065
|
article
|
| 9 |
Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors
|
Sprauten, M.
|
|
|
26 |
10 |
p. 2133-2140
|
article
|
| 10 |
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer
|
Jiang, D.M.
|
|
|
26 |
10 |
p. 2102-2106
|
article
|
| 11 |
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
|
Ryu, M.-H.
|
|
|
26 |
10 |
p. 2097-2101
|
article
|
| 12 |
Editorial board
|
|
|
|
26 |
10 |
p. ii-iii
|
article
|
| 13 |
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
|
Planchard, D.
|
|
|
26 |
10 |
p. 2073-2078
|
article
|
| 14 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk
|
Spina, M.
|
|
|
26 |
10 |
p. 2155-2161
|
article
|
| 15 |
Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?
|
Ning, J.
|
|
|
26 |
10 |
p. 2161-2168
|
article
|
| 16 |
Health care in the United States—basic human right or entitlement?
|
Jones, G.H.
|
|
|
26 |
10 |
p. 2193-2195
|
article
|
| 17 |
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model
|
Maia, A.R.R.
|
|
|
26 |
10 |
p. 2180-2192
|
article
|
| 18 |
Journey to a faraway land
|
Alkan, A.
|
|
|
26 |
10 |
p. 2200
|
article
|
| 19 |
MiR-29c downregulation contributes to metastatic progression in colorectal cancer
|
Cristóbal, I.
|
|
|
26 |
10 |
p. 2199-2200
|
article
|
| 20 |
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial
|
Ueda, T.
|
|
|
26 |
10 |
p. 2149-2154
|
article
|
| 21 |
Primum non nocere
|
Templeton, A.J.
|
|
|
26 |
10 |
p. 2197-2198
|
article
|
| 22 |
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
|
Libé, R.
|
|
|
26 |
10 |
p. 2119-2125
|
article
|
| 23 |
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design
|
Gerety, E.L.
|
|
|
26 |
10 |
p. 2113-2118
|
article
|
| 24 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
|
Middleton, M.R.
|
|
|
26 |
10 |
p. 2173-2179
|
article
|
| 25 |
Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management
|
McLellan, B.
|
|
|
26 |
10 |
p. 2017-2026
|
article
|
| 26 |
Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga
|
Aapro, M.
|
|
|
26 |
10 |
p. 2198-2199
|
article
|
| 27 |
Reply to the letter to the editor ‘Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy’ by Siva et al.
|
de Baère, T.
|
|
|
26 |
10 |
p. 2196-2197
|
article
|
| 28 |
Reply to the letter to the editor ‘Flaws in the trial design of IFCT-0802’ by Gyawali et al.
|
Pujol, J.-L.
|
|
|
26 |
10 |
p. 2199
|
article
|
| 29 |
Reply to the letter to the editor ‘Journey to a faraway land’ by Alkan et al.
|
Hartkopf, A.D.
|
|
|
26 |
10 |
p. 2200-2201
|
article
|
| 30 |
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) †
|
Bompas, E.
|
|
|
26 |
10 |
p. 2168-2173
|
article
|
| 31 |
Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria
|
Heller, G.
|
|
|
26 |
10 |
p. 2012-2016
|
article
|
| 32 |
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
|
Bracarda, S.
|
|
|
26 |
10 |
p. 2107-2113
|
article
|
| 33 |
Table of Contents
|
|
|
|
26 |
10 |
p. iv-vi
|
article
|
| 34 |
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
|
Ledermann, J.A.
|
|
|
26 |
10 |
p. 2034-2043
|
article
|
| 35 |
The new therapeutical scenario of Hodgkin lymphoma
|
Stathis, A.
|
|
|
26 |
10 |
p. 2026-2033
|
article
|
| 36 |
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET…
|
Scagliotti, G.V.
|
|
|
26 |
10 |
p. 2007-2009
|
article
|
| 37 |
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
|
Chi, K.
|
|
|
26 |
10 |
p. 2044-2056
|
article
|
| 38 |
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
|
Rulli, E.
|
|
|
26 |
10 |
p. 2079-2084
|
article
|
Journal description